CD274 and Hodgkins lymphoma: Previous clinical studies have demonstrated that radiotherapy combined with PD-1/PD-L1 inhibitors has long-lasting antitumor activity in advanced or metastatic melanoma (2), non-small cell lung cancer (NSCLC) (3), Hodgkin lymphoma (HL), renal cell carcinoma (RCC) and other cancer types (4).